Titanovo Logo
Back to Cell Types

NCI-H2228Homo sapiens (Human)Cancer cell line

Also known as: NCIH2228, H-2228, H2228, HC2228

🤖 AI SummaryBased on 14 publications

Quick Overview

Human lung cancer cell line with ALK fusion and potential for drug resistance studies.

Detailed Summary

The NCI-H2228 cell line is a human non-small cell lung cancer (NSCLC) cell line derived from a patient with metastatic disease. It is characterized by the presence of the EML4-ALK fusion gene, which is a key driver in certain subsets of NSCLC. This cell line has been used in studies to investigate the efficacy of ALK inhibitors, such as crizotinib, and to understand mechanisms of drug resistance. Research has shown that NCI-H2228 exhibits sensitivity to ALK-targeted therapies but can develop resistance through secondary mutations. It is also noted for its utility in studying the molecular pathways involved in tumor progression and response to treatment.

Research Applications

ALK inhibitor resistance studiesDrug sensitivity profilingMolecular pathway analysisCancer genomics

Key Characteristics

EML4-ALK fusionSensitivity to crizotinibResistance mechanismsMetastatic origin
Generated on 6/17/2025

Basic Information

Database IDCVCL_1543
SpeciesHomo sapiens (Human)
Tissue SourceLung[UBERON:UBERON_0002048]

Donor Information

Age CategoryUnknown
SexFemale

Disease Information

DiseaseLung adenocarcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeATCC
Source IDACH-000447_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Gln331Ter (c.991C>T)Homozygous-PubMed=29970484, PubMed=15287027
Gene fusionALKALK-PTPN3--from parent cell line NCI-H2228
Gene fusionALKEML4-ALK-E6A20 v3 fusionPubMed=35933914, PubMed=31882684

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
11
D16S539
11,13
D18S51
16
D19S433
14,15
D21S11
28,30
D2S1338
17
D3S1358
16,18
D5S818
12
D7S820
11
D8S1179
13
FGA
21,22
Penta D
11,13
Penta E
11,16
TH01
7,8
TPOX
11
vWA
15,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOIPubMedPMC

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.

Jimenez C.R.

J. Proteomics 196:106-119(2019).

DOIPubMed

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

DOIPubMedPMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Engelman J.A.

Cancer Discov. 4:662-673(2014).

DOIPubMedPMC

Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.

Chung D.H., Heo D.S.

J. Thorac. Oncol. 8:415-422(2013).

DOIPubMed

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing.

Lee J., Choi S.-J., Kim S., Lee J.-E., Kim J., Lee S., Kim J.

Genes Chromosomes Cancer 51:590-597(2012).

DOIPubMed

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Janne P.A.

Clin. Cancer Res. 14:4275-4283(2008).

DOIPubMedPMC

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

DOIPubMed

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

DOIPubMed

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

DOIPubMed

Insulin-like growth factor expression in human cancer cell lines.";

Grimley C., Battey J., Mulshine J.L., Cuttitta F.

J. Biol. Chem. 271:11477-11483(1996).

DOIPubMed

Loss of spindly sensitizes EML4-ALK v3 lung cancer cells to HSP90 inhibitors.

Workman P.

bioRxiv 2022:06.08.495301-06.08.495301(2022).

DOI

Web Resources

tcpaportal.org